Implantable Islet Cells May Control Diabetes Without Insulin Injections
Researchers at the Massachusetts Institute of Technology (MIT) are developing an innovative device aimed at diabetes management. This device is designed to contain insulin-producing cells that can potentially eliminate the need for daily insulin injections. Encapsulated to avoid immune rejection, it is also equipped with a built-in oxygen generator to ensure the cells remain healthy.
Currently, diabetes patients face a daily struggle of monitoring their blood sugar and administering insulin. The new study demonstrates that these encapsulated pancreatic islet cells can survive for at least 90 days within the body and effectively manage blood sugar levels in implanted mice.
“Islet cell therapy can change lives for patients,” noted Daniel Anderson, a professor at MIT’s Department of Chemical Engineering. He emphasized that existing treatments often require immune suppression, which can have serious side effects. The aim now is to offer the benefits of cell therapy without the downsides of those medications.
Insulin on Demand
Islet cell transplants are already used in treating diabetes, but the cells often come from human donors, requiring patients to take immunosuppressants to fend off rejection. Encapsulating the cells is one alternative, yet it introduces new issues, particularly concerning oxygen supply.
Anderson and colleagues have created an innovative encapsulation device featuring an oxygen generator. This generator utilizes a proton-exchange membrane to convert water vapor into hydrogen and oxygen. The hydrogen is safely dispersed, while the oxygen is stored and delivered to the islet cells through a specialized membrane.
This approach allowed the cells to produce insulin for up to a month post-implantation in mice.
“A month shows promise, but we need to extend this duration significantly,” said lead researcher Siddharth Krishnan. Improvements in waterproofing, durability, and electronic efficiency of the device have been made to boost its longevity. The device is powered wirelessly through an external antenna, enhancing the oxygen generation process and allowing cells to produce insulin more effectively.
Protein Factories
In additional trials with rats and mice, the device demonstrated functionality for at least 90 days after implantation, successfully maintaining appropriate blood sugar levels. When islet cells from induced pluripotent stem cells were used, the results were similarly positive, although they didn’t completely reverse diabetes.
“If we can push the cells to mature longer, we’re hopeful they can regulate diabetes even better,” said Matthew Bochenek, another lead author. The researchers envision extending the device’s lifespan in the body to possibly two years or more.
Anderson highlighted the significance of achieving long-term viability for the islets. “If placed in the right environment, these cells show potential for extended survival,” he remarked. The team is also interested in using this technology to produce other beneficial proteins, suggesting a future where devices create therapeutic proteins continuously in the body, eliminating the need for repeated medical procedures.
